文献速递慢性肾脏病

CKD疾病修饰治疗临床试验中的衰弱评估与疗效

Frailty Assessment and Treatment Effects in Clinical Trials of Disease-Modifying Therapies for CKD.
PubMed 文献 · Am J Kidney Dis · 2026-10-31

该叙述性综述探讨了CKD疾病修饰治疗临床试验中衰弱评估的现状与疗效差异。综述发现近期多项试验虽未正式评估衰弱,但通过替代指标分层分析显示治疗获益一致,且在高衰弱亚组中可能获益更大。然而现有替代指标可能无法全面反映衰弱的多维性,影响治疗决策。

要点

  • 近期CKD疾病修饰治疗试验中,各衰弱分层均显示一致获益,高衰弱亚组可能获益更大
  • 这些试验均未正式评估衰弱,所用替代指标可能无法全面捕捉衰弱的多维性
  • 监管机构鼓励在临床研究中常规评估衰弱并按衰弱分层报告结局

核心结论

  • 近期CKD疾病修饰治疗试验中,各衰弱分层均显示一致获益,高衰弱亚组可能获益更大。
  • 这些试验均未正式评估衰弱,所用替代指标可能无法全面反映衰弱的多维性。

研究设计与样本

  • 叙述性综述,未报告系统检索策略或样本量。

主要发现

  • 近期多项CKD疾病修饰治疗临床试验评估了不同衰弱分层的治疗效应。
  • 这些试验报告了一致的治疗获益,且在高衰弱亚组中可能获益更大。
  • 所有试验均未正式评估衰弱,所用替代指标可能未充分捕捉衰弱的多维性。

临床怎么用

  • 临床研究中应常规评估衰弱并按衰弱分层报告结局,以指导治疗决策。

局限性

  • 现有试验未正式评估衰弱,替代指标可能无法全面反映衰弱的多维性。
  • 缺乏正式衰弱评估工具,限制了对衰弱患者治疗决策的指导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Frailty is common in chronic kidney disease (CKD) and is independently associated with disability and mortality. However, evidence on the optimal treatment of frail adults with CKD remains limited. Consequently, regulators have encouraged routine assessment of frailty and the reporting of outcomes stratified by frailty in clinical studies. In this narrative review, we found that several recent clinical trials of disease-modifying therapies for CKD evaluated treatment effects across frailty strata and reported consistent benefits, with potentially greater benefits in the highest frailty subgroup. However, frailty was not formally assessed in any of these trials, and the proxy measures used may not have fully captured the multidimensional aspects of frailty needed to inform treatment decisions.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Yang C, Chen D, Chepulis L, et al. Frailty Assessment and Treatment Effects in Clinical Trials of Disease-Modifying Therapies for CKD. Am J Kidney Dis. 2026. PMID: 42966593. doi:10.1053/j.ajkd.2026.06.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。